Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2026)

Recursion Pharmaceuticals has reported FCF Margin for 7 years, with the latest figure at 1253.11% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 35041.0% year-over-year to 1253.11%; the trailing twelve-month figure through Mar 2026 stood at 491.32% (up 17270.0% YoY), and the FY2025 full-year result was 506.52%, up 12719.0% from the prior year.
• FCF Margin for Q1 2026 stood at 1253.11%, down from 147.77% in the prior quarter.
• The five-year high for FCF Margin was 1369.7% in Q1 2022, with the low at 2567.71% in Q4 2024.
• Historically, FCF Margin has averaged 721.07% across 5 years, with a median of 610.23% in 2023.
• Annual changes were most pronounced in 2022 — FCF Margin soared 332797 bps — and 2025, when it plunged 201874 bps.
• Recursion Pharmaceuticals' FCF Margin stood at 575.56% in 2022, then declined by 6 bps to 611.77% in 2023, then sank by 320 bps to 2567.71% in 2024, then surged by 94 bps to 147.77% in 2025, then sank by 748 bps to 1253.11% in 2026.
• The last three FCF Margin figures came in at 1253.11% (Q1 2026), 147.77% (Q4 2025), and 2263.3% (Q3 2025), per Business Quant data.